ARCUTIS BIOTHERAPEUTIC

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

07 May 2025 08:18:26 By Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

06 May 2025 13:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 May 2025 13:00:00 By Nasdaq GlobeNewswire

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

17 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Chief Financial Officer Transition

10 Apr 2025 13:30:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2025 13:00:00 By Nasdaq GlobeNewswire

Arcutis and Padagis Agree to Stay Patent Lawsuit

02 Apr 2025 10:16:46 By Nasdaq GlobeNewswire

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

27 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

07 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Mar 2025 13:00:00 By Nasdaq GlobeNewswire

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

28 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis 

26 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

25 Feb 2025 13:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

24 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

18 Feb 2025 13:35:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Feb 2025 13:00:00 By Nasdaq GlobeNewswire

Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

27 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

12 Jan 2025 05:30:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jan 2025 13:00:00 By Nasdaq GlobeNewswire

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

16 Dec 2024 05:00:00 By Nasdaq GlobeNewswire